Inflammation & Cytokines in Orthopaedics (TNF-α, IL-1, IL-6)

What cytokines are. Cytokines are small secreted signalling proteins that act in autocrine, paracrine and sometimes endocrine fashion to coordinate inflammation, immunity and tissue repair. The families are the interleukins (IL), the tumour necrosis factors (TNF), the interferons, the chemokines and the growth factors.

The acute inflammatory response. The classic response to injury or infection, rubor, calor, dolor, tumor, functio laesa, is orchestrated by cytokines. Tissue macrophages and recruited cells release the pro-inflammatory trio TNF-α, IL-1 and IL-6, which cause vasodilation, increased vascular permeability and leukocyte recruitment locally and the systemic acute-phase response (fever, CRP). Resolution is driven by the anti-inflammatory mediators IL-10, TGF-β and IL-1Ra and by pro-resolution lipids.

Two faces. Sustained pro-inflammatory signalling (TNF-α, IL-1, IL-6, IL-17) drives cartilage degradation, bone erosion and synovitis: the basis of rheumatoid arthritis, and a contributor to periprosthetic osteolysis and inflammatory bone loss. The same cytokines initiate the inflammatory phase of fracture healing and host defence against infection. Inflammation is a necessary repair signal, and the goal is to control excess, not abolish it.

How the cytokines are switched on. Before any cytokine is released the innate immune system must sense danger, and that upstream step is examinable. Pattern-recognition receptors, chiefly the Toll-like receptors (TLRs) on macrophages, detect PAMPs (pathogen-associated molecular patterns, e.g. bacterial LPS) and DAMPs (damage-associated molecular patterns released by injured or necrotic cells). The same sensing lets wear debris act as a "sterile" danger signal in periprosthetic osteolysis.

From receptor to cytokine. Engagement drives NF-κB transcription of pro-inflammatory genes, producing TNF-α, IL-6 and pro-IL-1β, an inactive precursor. The NLRP3 inflammasome is the second signal: it assembles and activates caspase-1, which cleaves pro-IL-1β into active IL-1β, the molecular origin of the IL-1 the rest of this topic discusses. This is the pathway that monosodium-urate crystals activate in gout (and a proposed mechanism for crystal- and particle-induced "sterile" inflammation), and it is the rationale for IL-1 blockade with anakinra and for colchicine.

The shared signalling. Osteoimmunology describes the signalling shared between the immune and skeletal systems. The unifying mechanism of inflammatory bone loss is that the pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-17) up-regulate RANKL and reduce OPG on osteoblast-lineage and stromal cells, tipping the RANKL:OPG ratio toward osteoclast formation and activity, and so toward bone erosion.

Why erosions do not heal. TNF-α and IL-1 can also act more directly on osteoclast precursors, and they impair osteoblastic repair, so erosions both enlarge and fail to heal. This is the molecular engine behind the joint destruction of inflammatory arthritis.

View larger

View larger

Rheumatoid arthritis. Cells in the inflamed synovium and pannus elaborate TNF-α, IL-1, IL-6 and IL-17, which drive synovitis and, through the RANK/RANKL/OPG pathway, articular bone erosions and periarticular osteoporosis. This mechanistic understanding underpins biologic therapy.

View larger

Periprosthetic osteolysis. Wear debris, for example polyethylene particles, is phagocytosed by macrophages, which release TNF-α, IL-1 and IL-6 and up-regulate RANKL, driving osteoclastic bone resorption around the implant: the cytokine basis of aseptic loosening and osteolysis. Debris also suppresses the anti-osteoclastogenic interferon-gamma, so it pushes the balance from both ends.

Size matters as well as volume. Submicron particles are the most macrophage-reactive, so a bearing that wears less by weight is not automatically less osteolytic if the particles it sheds are smaller and more numerous. Judge a bearing on biological reactivity, not on volumetric wear rate alone.

View larger

Infection and sepsis. Pathogen products trigger macrophage release of TNF-α, IL-1 and IL-6, producing local inflammation, the acute-phase response (CRP/ESR) used diagnostically and, if excessive, the systemic inflammatory response and sepsis. The same mediators contribute to septic bone and joint destruction.

View larger

Fracture healing. The inflammatory phase of fracture healing depends on a controlled, early burst of IL-1, IL-6 and TNF-α, which recruits cells and initiates repair. This is why indiscriminate anti-inflammatory blockade, a theoretical concern with NSAIDs and COX-2 inhibitors, may impair union.

View larger

The acute-phase response: CRP versus ESR. The systemic arm of the cytokine response is driven chiefly by IL-6 acting on hepatocytes, and it produces the two inflammatory markers used daily in orthopaedics. Their kinetics are the examinable point.

CRP. A hepatocyte-synthesised acute-phase protein that rises within about 6 hours, peaks around 48 hours and has a short half-life of about 19 hours, so it falls quickly once inflammation settles. That fast on and off makes it the marker for monitoring an acute process: the post-operative course, response to treatment and suspected periprosthetic joint infection.

ESR. An indirect marker that reflects fibrinogen- and immunoglobulin-driven red-cell rouleaux. It rises and falls slowly over weeks and is confounded by age, anaemia, pregnancy and paraproteins, so it lags and is less useful for tracking rapid change.

Using them. A normal CRP and ESR together have a high negative predictive value for screening PJI, and a persistently rising or non-falling CRP after arthroplasty raises the suspicion of infection. Tocilizumab, the anti-IL-6 receptor antibody, suppresses CRP, so the marker can be falsely reassuring in a patient on that biologic.

Where the drugs act. The biologics each target one of the cytokines above, and denosumab blocks RANKL downstream of them.

View larger

The peri-operative point. Biologics are immunosuppressive, so peri-operative management balances infection and wound-healing risk against disease flare, typically by timing surgery around the drug's dosing interval and following rheumatology and society guidance. Always screen for latent infection, for example TB, before starting anti-TNF therapy.

How the signal gets into the cell. The biologics are extracellular antibodies; examiners also want the intracellular pathways. TNF-α (via TNFR) and IL-1 (via IL-1R and MyD88) signal mainly through NF-κB and the MAPK cascades to switch on inflammatory genes. IL-6 (via IL-6R and gp130) and the interferons signal through the JAK-STAT pathway, notably STAT3.

The JAK inhibitors. Tofacitinib, baricitinib and upadacitinib are oral targeted-synthetic DMARDs that block the Janus kinases and so dampen JAK-STAT-dependent cytokine signalling inside the cell: a different mechanism from the injectable biologics with the same anti-cytokine goal. Like the biologics they are immunosuppressive (serious infection, herpes-zoster reactivation), and they carry class warnings for VTE and major cardiovascular events and malignancy, the ORAL Surveillance signal. The ACR/AAHKS perioperative guideline withholds JAK inhibitors before elective arthroplasty, unlike traditional DMARDs, which are continued.

View larger